Alpha Cognition Inc (ACOG)

Currency in USD
5.08
-0.26(-4.87%)
Closed·
5.080.00(0.00%)
·
ACOG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.875.36
52 wk Range
3.7511.54
Key Statistics
Prev. Close
5.34
Open
5.01
Day's Range
4.87-5.36
52 wk Range
3.75-11.54
Volume
111.42K
Average Volume (3m)
64.57K
1-Year Change
-8.1374%
Book Value / Share
2.88
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ACOG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
18.00
Upside
+254.33%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Alpha Cognition Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.

Alpha Cognition Inc Earnings Call Summary for Q4/2025

  • Q4 revenue reached $2.8M, full-year $10.2M, driven by ZUNVEYL; Q4 net loss $6.9M, full-year loss $20.7M with strong $66M cash position, debt-free.
  • ZUNVEYL dispensed 4,941 bottles in Q4, up 62% quarter-over-quarter, reaching 3,856 nursing homes as first new oral Alzheimer's treatment in 15+ years.
  • Company projects 2026 operating expenses of $54-58M for clinical studies and commercialization, targeting operational profitability by 2027.
  • Developing sublingual ZUNVEYL formulation to address dysphagia challenges; stock rose 0.56% aftermarket with analyst price target of $18.
Last Updated: 26/03/2026, 22:32
Read Full Transcript

Compare ACOG to Peers and Sector

Metrics to compare
ACOG
Peers
Sector
Relationship
P/E Ratio
−5.3x−2.3x−0.4x
PEG Ratio
−0.13−0.040.00
Price/Book
1.8x2.4x2.6x
Price / LTM Sales
10.8x8.0x3.1x
Upside (Analyst Target)
254.3%400.0%56.0%
Fair Value Upside
Unlock18.2%9.0%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 18.00
(+254.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy18.00+254.33%-MaintainNov 24, 2025
H.C. Wainwright
Buy18.00+254.33%20.00MaintainOct 21, 2025
H.C. Wainwright
Buy20.00+293.70%-MaintainJul 03, 2025

Earnings

Latest Release
Nov 13, 2025
EPS / Forecast
-0.30 / -0.82
Revenue / Forecast
2.84M / --
EPS Revisions
Last 90 days

ACOG Income Statement

People Also Watch

3.350
ATAI
-5.37%
243.48
COHR
+0.08%
6.91
VNDA
-2.95%
45.7300
RBRK
-3.91%

FAQ

What Is the Alpha Cognition (ACOG) Stock Price Today?

The Alpha Cognition stock price today is 5.08 USD.

What Stock Exchange Does Alpha Cognition Trade On?

Alpha Cognition is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Alpha Cognition?

The stock symbol for Alpha Cognition is "ACOG."

What Is the Alpha Cognition Market Cap?

As of today, Alpha Cognition market cap is 110.45M USD.

What Is Alpha Cognition's Earnings Per Share (TTM)?

The Alpha Cognition EPS (TTM) is -1.17.

From a Technical Analysis Perspective, Is ACOG a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Alpha Cognition Stock Split?

Alpha Cognition has split 1 times.

What is the current trading status of Alpha Cognition (ACOG)?

As of Mar 29, 2026, Alpha Cognition (ACOG) is trading at a price of 5.08 USD, with a previous close of 5.34 USD. The stock has fluctuated within a day range of 4.87 USD to 5.36 USD, while its 52-week range spans from 3.75 USD to 11.54 USD.

What Is Alpha Cognition (ACOG) Price Target According to Analysts?

The average 12-month price target for Alpha Cognition is 18.00 USD, with a high estimate of 18 USD and a low estimate of 18 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +254.33% Upside potential.

What Is the ACOG Premarket Price?

ACOG's last pre-market stock price is 5.01 USD. The pre-market share volume is 1,390.00, and the stock has decreased by -0.33, or -6.18%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.